As we have previously reported, the Inflation Reduction Act (IRA) changed the government’s treatment of certain prescription drugs under the Medicare program by directing the Secretary of Health and Human Services (HHS) to establish the Drug Price Negotiation Program (“the Program”; see here for a full recap of the Program’s structure). The IRA instructed HHS select certain “high priced” Medicare-covered drugs for inclusion in the first year of the Program. On August 29, 2023, HHS announced the 10 drugs that would be included in the first year of the Program. Of the 10 selected drugs, 3 are biologics (ENBREL, STELARA, and the FIASP and NOVOLOG products) while the remainder are small-molecule drugs.
The Program establishes “price negotiations” with the Centers for Medicare & Medicaid Services (CMS) to obtain a “Maximum Fair Price (MFP).” The MFP must be set at no more than 40-75% of the lower of (a) the drug’s non-Federal average manufacturer price for the year 2021, (b) the drug’s non-Federal average manufacturer price for the year prior to selection; or (c) the average sales price or wholesale acquisition cost for the year prior to selection. The Program requires the final MFP for drugs selected for the first year of the program be published by September 1, 2024.
On August 15, 2024, the CMS announced the negotiated MFPs for the first 10 drugs selected for Medicare Price Negotiation. The reduction in prices range from 38 to 79 percent of the 2023 listed prices for the drugs. The MFPs for the first 10 selected drugs will take effect starting January 1, 2026.
For those interested in more detail about the IRA, please visit our Goodwin IRA webpage, where you can view and download material from our previous webinars covering additional detail and background on the IRA, including guidance from the CMS on implementation of the Program, presented by Goodwin Life Sciences Regulatory & Compliance partner Matt Wetzel. We are also be monitoring pending legal challenges to the IRA and tracking updates on the IRA Litigation Tracker, which are available on our IRA webpage.
The post The Centers for Medicare & Medicaid Services Announces Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation appeared first on Big Molecule Watch.